SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today the final results of a Phase I clinical study demonstrating safe and effective treatment of metastatic melanoma in the first-in-man trial of a DNA-based therapy designed to express a therapeutic protein through in vivo delivery using electroporation. The data was presented in the peer-reviewed Journal of Clinical Oncology in a paper prepared by Drs. Adil Daud, Richard Heller et al, titled, “Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma.”
